Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Feb 16, 2023 10:20am
57 Views
Post# 35289713

RE:Warrants

RE:WarrantsJust some minor corrections - the exercise price is somewhere around US$3.15 per share and total proceeds will be around $24 millionif I recall correctly. But you may have been using Canadian dollars and that may account for the difference. 

jfm1330 wrote: We are now one year away from expiration of the 7.25 millions warrants with an exercize price of 4 $ Canadian. So the SP should triple and more to have these warrants exercized. If in some way they would be exercized, it would bring close to 30 M$ to Thera, and if not, from a dilution point of view, it would give them some room to do something. The best case scenario would be to have the SP just below 4$ in February 2024, then come with a good news, a do a financing at a higher price. I know, it's wishful thinking on my part. 


<< Previous
Bullboard Posts
Next >>